Advertisement

Advertisement

EHA2022 Congress

lymphoma

Anna Sureda, MD, PhD, on Large B-Cell Lymphoma: New Data on Axicabtagene Ciloleucel vs Standard of Care

Anna Sureda, MD, PhD, of the University of Barcelona and the Catalan Institute of Oncology, discusses phase III clinical and patient-reported outcomes from the ZUMA-7 trial, which showed that axicabta...

leukemia

Harry P. Erba, MD, PhD, on AML: New Data on Quizartinib Plus Standard Chemotherapy

Harry P. Erba, MD, PhD, of Duke Cancer Institute, discusses potentially practice-changing phase III results from the QuANTUM-First trial, which showed that adding quizartinib to standard chemotherapy ...

Lymphoma
Immunotherapy

Expert Point of View: Alexey V. Danilov, MD, PhD

According to Alexey V. Danilov, MD, PhD, Professor and Co-Director, Toni Stephenson Lymphoma Center, City of Hope, diffuse large B-cell lymphoma (DLBCL) refractory to chemotherapy represents an unmet ...

Lymphoma
Immunotherapy

Epcoritamab Under Study in Difficult-to-Treat Large B-Cell Lymphoma

Subcutaneous epcoritamab, a bispecific antibody, has demonstrated deep and durable responses in a large expansion cohort of patients with relapsed or refractory large B-cell lymphoma (LBCL), according...

leukemia

Nicholas J. Short, MD, on ALL: Updated Phase II Study Results on Ponatinib and Blinatumomab

Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses updated results from a phase II study that suggests the chemotherapy-free regimen of simultaneous ponatinib and b...

Leukemia

Study Reports Time-Limited Venetoclax-Based Regimens of Benefit in Front-Line Treatment of CLL

Time-limited venetoclax-based regimens provide deeper and more durable remissions than chemoimmunotherapy combinations in patients with previously untreated chronic lymphocytic leukemia (CLL), regardl...

lymphoma
immunotherapy

Michael Dickinson, MBBS, on DLBCL: Phase II Expansion Results on Glofitamab

Michael Dickinson, MBBS, of the Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and The University of Melbourne, discusses new data, which showed that fixed-duration glofitamab induces du...

Leukemia

Phase III Trial Reports Quizartinib Doubles Overall Survival in FLT3-ITD–Positive AML

A new treatment option has doubled overall survival for a difficult-to-treat subset of patients with acute myeloid leukemia (AML), according to data presented during the Presidential Symposium at the ...

Leukemia

Magrolimab Plus Azacitidine in TP53-Mutant AML

High-risk patients with TP53-mutated acute myeloid leukemia (AML) have limited treatment options and very poor prognoses. Magrolimab is a monoclonal antibody designed to block CD47, an immune macropha...

Leukemia
Genomics/Genetics

Triplet Combination Therapy Yields High Response Rates in Patients With FLT3-Mutated AML

FLT3-ITD–mutated acute myeloid leukemia (AML) is an aggressive disease usually resistant to available treatment options, resulting in high front-line response rates but short response durations and lo...

Leukemia
Myelodysplastic Syndromes
Genomics/Genetics

Targeted Therapy Emavusertib Shows Activity in Patients With MDS or AML With Specific Mutations

Mutations in SF3B1 and U2AF1 can drive overexpression of activated IRAK4—which regulates inflammation and promotes cancer cell growth and survival—and are associated with a poor prognosis for patients...

Lymphoma
Immunotherapy

Allogeneic CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoma

Patients with relapsed or refractory T-cell lymphoma have limited treatment options. Chimeric antigen receptor (CAR) T-cell therapy has been challenging in these patients because of the state of their...

Leukemia
Immunotherapy

Ponatinib Plus Blinatumomab for Patients With Philadelphia Chromosome–Positive ALL

The tyrosine kinase inhibitor ponatinib and monoclonal antibody blinatumomab—which targets CD19 on leukemia cells—are highly effective as monotherapies for patients with Philadelphia chromosome–positi...

Advertisement

Advertisement



Advertisement